Gilead Sciences, Inc. (NASDAQ:GILD) Position Trimmed by D.A. Davidson & CO.

D.A. Davidson & CO. reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 21.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 82,517 shares of the biopharmaceutical company’s stock after selling 22,070 shares during the quarter. D.A. Davidson & CO.’s holdings in Gilead Sciences were worth $6,918,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of GILD. Kennedy Capital Management LLC bought a new position in Gilead Sciences in the first quarter worth about $2,946,000. B. Riley Wealth Advisors Inc. raised its position in shares of Gilead Sciences by 2.2% during the 1st quarter. B. Riley Wealth Advisors Inc. now owns 28,519 shares of the biopharmaceutical company’s stock worth $2,137,000 after purchasing an additional 604 shares during the period. Atria Investments Inc lifted its holdings in shares of Gilead Sciences by 16.2% in the 1st quarter. Atria Investments Inc now owns 89,515 shares of the biopharmaceutical company’s stock worth $6,557,000 after purchasing an additional 12,507 shares during the last quarter. Cetera Investment Advisers boosted its position in Gilead Sciences by 127.6% during the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock valued at $15,668,000 after purchasing an additional 119,909 shares during the period. Finally, Cetera Advisors LLC grew its stake in Gilead Sciences by 167.2% during the 1st quarter. Cetera Advisors LLC now owns 82,786 shares of the biopharmaceutical company’s stock worth $6,064,000 after buying an additional 51,801 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 1.2 %

Shares of Gilead Sciences stock opened at $92.41 on Thursday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The firm has a market capitalization of $115.17 billion, a PE ratio of 1,026.78, a price-to-earnings-growth ratio of 2.81 and a beta of 0.17. The stock’s fifty day moving average is $87.91 and its 200-day moving average is $77.42.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the previous year, the company earned $2.29 EPS. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. Equities analysts anticipate that Gilead Sciences, Inc. will post 4.37 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.33%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 3,422.22%.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This represents a 1.96 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 63,735 shares of company stock worth $5,589,030 over the last quarter. Corporate insiders own 0.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on GILD shares. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Daiwa America raised shares of Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Citigroup assumed coverage on Gilead Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $125.00 price objective for the company. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Finally, Mizuho boosted their price target on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Twelve research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $95.41.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.